DMD Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on October 4, 2005; DOI: 10.1124/dmd.104.003434


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.104.003434v1
34/1/8    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lambert, J. D.
Right arrow Articles by Yang, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lambert, J. D.
Right arrow Articles by Yang, C. S.


Received for publication January 21, 2005.
Revised September 21, 2005.
Accepted for publication September 23, 2005.

Dose-dependent Levels of Epigallocatechin-3-gallate in Human Colon Cancer Cells and Mouse Plasma and Tissues

Joshua D. Lambert 1, Mao-Jung Lee 1, Lauren Diamond 1, Jihyeung Ju 1, Jungil Hong 1, Mousumi Bose 1, Harold L. Newmark 1, Chung S. Yang 1*

1 Rutgers University

* Address correspondence to: E-mail: csyang{at}rci.rutgers.edu

Abstract

Epigallocatechin-3-gallate (EGCG, mol. formula: C22H18011) is the most abundant catechin in green tea (Camellia sinensis Theaceae). Both EGCG and green tea have been shown to have cancer preventive activity in a number of animal models, and numerous mechanisms have been proposed based on studies with human cell lines. EGCG has been shown to undergo extensive biotransformation to yield methylated and glucuronidated metabolites in mice, rats, and humans. In the present study, we determined the concentration-dependent uptake of EGCG by HT-29 human colon cancer cells (20 - 600 µM) and the dose-dependence of EGCG plasma and tissue levels following a single dose of EGCG (50 - 2000 mg/kg, i.g.) to male CF-1 mice. The cytosolic levels of EGCG were linear with respect to extracellular concentration of EGCG following treatment of HT-29 cells for 2 h (915.3 - 6851.6 µg/g). In vivo EGCG exhibited a linear doserelationship in the plasma (0.03 - 4.17 µg/mL), prostate (0.01 - 0.91 µg/g), and liver (0.09 - 18.3 µg/g). In the small intestine and colon, however, the levels of EGCG plateaued between 500 and 2000 mg/kg, i.g. These results suggest that absorption of EGCG from the small intestine is largely via passive diffusion, however, at high concentrations, the small intestinal and colonic tissues become saturated. The levels of 4"-O-methylEGCG and 4',4"-di-O-methylEGCG parallel those of EGCG with respect to dose. The present study provides information with respect to what concentrations of EGCG are achieveable in mice and may guide dose- selection for future cancer chemoprevention studies with EGCG.


Key words: absorption, bioavailability, glucuronidation, HPLC, in vitro-in vivo scaling, pharmacokinetics


This article has been cited by other articles:


Home page
J. Nutr.Home page
M. Fang, D. Chen, and C. S. Yang
Dietary Polyphenols May Affect DNA Methylation
J. Nutr., January 1, 2007; 137(1): 223S - 228S.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
S. M. Henning, W. Aronson, Y. Niu, F. Conde, N. H. Lee, N. P. Seeram, R.-P. Lee, J. Lu, D. M. Harris, A. Moro, et al.
Tea Polyphenols and Theaflavins Are Present in Prostate Tissue of Humans and Mice after Green and Black Tea Consumption
J. Nutr., July 1, 2006; 136(7): 1839 - 1843.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.